11th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head & Neck Cancer

11th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head & Neck Cancer is organized by Biomedical Learning Institute (BMLI) and wil be held on Oct 27, 2018 at San Francisco Airport Marriott Waterfront, Burlingame, California, United States of America.

The target audience for this medical event is lung cancer and head and neck cancer medical oncologists, pathologists, radiologists, surgeons, fellows, oncology pharmacists, oncology nurses, nurse practitioners, physician assistants and other allied healthcare professionals. This CME Conference has been approved for a maximum of 8.25 AMA PRA Category 1 Credits.

Conference Description :
The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer and head and neck cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, especially today with the wider availability of NGS testing. This symposium will integrate many new and emerging therapies into best practices for their lung cancer and head and neck cancer patients including immune therapy, novel targeted therapies, and novel uses of chemotherapy in various combinations with immune therapies. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.

Conference Objectives are :
Physicians:
• Understand how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Evaluate when to order NGS testing for treatment-naive patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.

Nurses:
• Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Describe when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.
• List the options for treating relapsed patients with nonsquamous or squamous Non-Small Cell Lung Cancer.

Pharmacists :
• Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Describe when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.
• List the options for treating relapsed patients with nonsquamous or squamous Non-Small Cell Lung Cancer.

Additional details will be posted as soon as they are available.